Northport

Researchers are comparing the effectiveness of two different combinations of immunotherapy drugs with chemotherapy for adults with stage IV or recurrent non-squamous non-small cell lung cancer that has PD-L1 expression of 1% or higher. This phase 3, randomized study focuses on participants who have not previously received systemic treatment for advanced disease. The goal is to determine which combination better improves overall survival and other outcomes in this patient group. Participants will be randomly assigned to receive either Nivolumab plus Relatlimab combined with chemotherapy or Pembrolizumab combined with chemotherapy. The chemotherapy drugs used include Carboplatin, Pemetrexed, or Cisplatin, given in specified doses on scheduled days. Treatment is given as first-line therapy for their cancer, with dosing details managed throughout the study period. During the study, participants will undergo imaging scans like CT or MRI to measure disease status, and blood tests to monitor safety and side effects. The main outcome measured is overall survival over up to five years, along with progression-free survival, response rates, duration of response, and adverse events. Researchers will also assess symptoms related to lung cancer over two years. Participants are monitored regularly to track these outcomes and ensure safety throughout the study duration, which may last several years.

This research aims to compare the impact of Exposure and Response Prevention ERP therapy versus a stress management training control on Veterans with Obsessive Compulsive Disorder OCD, including those with both OCD and posttraumatic stress disorder PTSD. The study will evaluate how these treatments affect Veterans functioning, quality of life, and OCD symptoms. Additionally, the study will explore the potential for implementing ERP in Veterans Affairs VA mental health settings through mixed-methods evaluation. Participants will be randomly assigned to receive either 16 weekly sessions of ERP or 16 weekly sessions of stress management training, both delivered via video telehealth VTH. ERP sessions, lasting 90 minutes each, involve psychoeducation, assessment, exposures to feared situations, and homework assignments focused on coping with OCD triggers. Stress management training includes psychoeducation and sessions teaching relaxation and coping skills. Assessments will be conducted after treatment and six months later. ERP participants will also provide feedback on treatment satisfaction and participate in qualitative interviews. Veterans will be involved in completing assessments of their work and social adjustment, quality of life, and OCD symptoms at baseline, post-treatment, and six months post-treatment. Researchers will collect data on treatment effects and implementation potential. Therapy sessions will be audio-recorded. The total participation lasts through treatment and follow-up visits up to six months after treatment completion.

Researchers are evaluating whether olomorasib combined with pembrolizumab or durvalumab is more effective than these immunotherapies alone in participants with KRAS G12C-mutant non-small cell lung cancer NSCLC. The study focuses on two groups those with resected NSCLC and those with unresectable NSCLC. This Phase 3 trial aims to assess disease-free survival and progression-free survival among these participants over an estimated period of up to 3 years. Participants will receive either olomorasib or a placebo orally along with pembrolizumab or durvalumab administered intravenously for up to one year. After this combination phase, participants continue with olomorasib or placebo alone for up to a total of three years of treatment. The study includes randomized, double-blind groups to compare these combinations in both resected and unresectable NSCLC. During the study, participants undergo regular assessments to monitor disease progression, overall survival, and quality of life using questionnaires and imaging. Researchers measure outcomes such as disease-free survival, progression-free survival, response rates, and symptom changes related to NSCLC. The study also tracks safety and health impacts over the treatment period, which may last up to three years for each participant.